To hear about similar clinical trials, please enter your email below
Trial Title:
Integrative Omics Analysis for Colorectal Cancer and Metastasis
NCT ID:
NCT05482529
Condition:
Colorectal Cancer
Conditions: Official terms:
Colorectal Neoplasms
Neoplasm Metastasis
Conditions: Keywords:
Integrative omics
colorectal cancer
distant metastasis
prognostic analysis
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
Integrative omics
Description:
Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible
Chromatin using sequencing), CUT&Tag（ Cleavage Under Targets and Tagmentation）to analyze
and predict candidate biomarkers of colorectal cancer and distant metastasis.
Arm group label:
colorectal cancer with metastasis
Summary:
The pathogenesis of Colorectal cancer (CRC) metastasis remains unclear.We collect
clinical data from our center and use Integrative omics to analyze and predict candidate
biomarkers of colorectal cancer and distant metastasis.
Detailed description:
Colorectal cancer (CRC), one of the most common malignant cancer around the world, CRC
patients with distant metastasis. However, the pathogenesis of metastasis remains
unclear. Integrative omics have begun to enable personalized medicine at an
extraordinarily detailed molecular level. All patients with colorectal cancer and
metastasis in our center who meet the inclusion criteria and exclusion criteria will be
enrolled. The specimen collected by surgery and clinical data will be collected . We use
Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible
Chromatin using sequencing), CUT&Tag（ Cleavage Under Targets and Tagmentation）to analyze
and predict candidate biomarkers of colorectal cancer and distant metastasis. This study
will contribute to understanding the molecular mechanism of CRC metastasis in depth and
contribute to the discovery of new appropriate molecular diagnostic and therapeutic
targets, and more accurately prognose long term outcome in patients with CRC.
Criteria for eligibility:
Study pop:
All patients with colorectal cancer and metastasis will be enrolled.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- colorectal adenocarcinoma by biopsy。
- at least 1 metastasis lesion comfirmed by at least 1 kind of imaging examination
(CT, MRI and PET-CT )
Exclusion Criteria:
- recent diagnosis with other malignancies
- can not tolerate the surgery
- history of serious mental illness
- pregnancy or lactating women
- the researchers believe the patients should not enrolled in
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Locations:
Facility:
Name:
Daping hospital
Address:
City:
Chongqing
Zip:
400042
Country:
China
Status:
Recruiting
Contact:
Last name:
fan Li, PhD
Phone:
68729350
Email:
levinecq@163.com
Start date:
August 1, 2022
Completion date:
December 31, 2025
Lead sponsor:
Agency:
fan li
Agency class:
Other
Source:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05482529
